F

Fresenius Medical Care

Operates dialysis facilities and renal care

Strategic Business Unit Head – Critical Care

Full-TimeDeadline 10/31/26
No salary listed
Expert
MBA
Gurugram, Haryana, India
In Person
Sales & Account ManagementField Sales, Account Management

About the job

Requirements
  • A postgraduate degree in Business is required; an MBA from a reputed institution is preferred, with additional qualification or deep exposure in clinical or life sciences as a strong differentiator.
  • At least 20 years of experience in healthcare, with strong orientation toward medical devices across commercial, market development, or business leadership functions.
  • A demonstrated track record of leading P&L responsibilities or SBU/business-unit ownership, ideally across multiple geographies or therapy segments within India.
  • Deep familiarity with the Indian healthcare ecosystem, including hospital procurement dynamics, institutional selling, key opinion leader engagement, and therapy adoption cycles.
  • Experience as a people leader managing layered, geographically distributed teams.
  • Strong executive presence and the ability to engage credibly with clinical, commercial, and organizational stakeholders.
Responsibilities
  • Develop and own the multi-year strategy for the Critical Care Strategic Business Unit, including therapy portfolio positioning, market development, competitive differentiation, and revenue growth architecture.
  • Translate the global Critical Care vision into an India-specific strategy across public, private, and emerging healthcare segments.
  • Own the Strategic Business Unit’s revenue, margin, and cost structure; drive resource allocation, pricing strategy, investment prioritization, and the annual operating plan.
  • Present business performance to the Managing Director and regional leadership.
  • Work with global product management and regional marketing to shape the India portfolio roadmap and identify therapy gaps, unmet clinical needs, market opportunities, and product and therapy development priorities.
  • Champion continuous renal replacement therapy, high-volume high-density hemodiafiltration, and adjacent critical care therapies with clinical and commercial rigor.
  • Define and execute market development across corporate chains, tertiary hospitals, government medical institutions, and emerging intensive care unit setups in Tier 2 and Tier 3 cities.
  • Drive revenue growth and target delivery while balancing short-term performance with long-term account and therapy development.
  • Own relationships with strategically significant hospital chains, government institutions, and academic medical centers.
  • Develop the government and institutional tender strategy, including procurement cycles, decision hierarchies, and state-level compliance requirements.
  • Define and govern the regional pricing framework for the Critical Care portfolio in alignment with global and regional guidelines.
  • Lead, inspire, and develop the Critical Care commercial organization, including Regional Managers, Product Specialists, and cross-functional partners.
  • Build the next generation of Critical Care leaders by identifying high-potential individuals, creating stretch opportunities, and developing structured plans with Human Resources.
  • Own workforce planning and organizational design, and partner with Human Resources on recruitment, onboarding, and capability frameworks.
  • Build and lead a national key opinion leader engagement program across critical care and nephrology.
  • Support and participate in clinical education initiatives, symposia, and publications.
  • Champion the clinical evidence base and work with medical affairs to generate India-relevant clinical data, real-world evidence, and therapy outcome metrics.
  • Represent Fresenius Medical Care at national and regional critical care and nephrology forums and engage with professional bodies, regulatory organizations, and government bodies.
  • Deliver Critical Care revenue and margin targets, market-share growth, new-account acquisition, therapy initiation, team productivity, regional coverage, key opinion leader activation, talent development, operating-plan execution, and strategic-account management.
Desired Qualifications
  • An MBA from a reputed institution.
  • Additional qualification or deep exposure in clinical or life sciences.
  • Experience in Critical Care, including continuous renal replacement therapy, hemodynamic monitoring, organ support, or adjacent therapy categories.
  • Experience leading P&L responsibilities or Strategic Business Unit/business-unit ownership across multiple geographies or therapy segments within India.

About the company

F

Fresenius Medical Care

View

Fresenius Medical Care North America runs a network of dialysis facilities and outpatient labs to deliver coordinated kidney care for hundreds of thousands of patients. It also offers specialty pharmacy and laboratory services and manufactures a wide range of dialysis equipment, disposables, and renal drugs. The company treats patients by providing dialysis and related care at its clinics, supported by the equipment, supplies, and medicines it develops and distributes. FMCNA differentiates itself through its size and integration as the world's largest fully integrated renal company, with a nationwide network covering care delivery, drugs, labs, and manufacturing, aiming to provide high-quality, convenient access to comprehensive services across North America.

Company Size

11-50

Company Stage

Late Stage VC

Total Funding

$40.2M

Headquarters

Waltham, Massachusetts

Founded

1996

Get referred to Fresenius Medical Care

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 operating income rose 23%, showing transformation gains reached profitability.
  • FME25+ delivered EUR 67 million savings in Q2 2026 and targets EUR 1.2 billion.
  • Real-world evidence studies in July and August 2026 strengthen high-volume hemodiafiltration adoption.

What critics are saying

  • The August 2026 outlook disappointed investors after dialysis growth stalled and shares fell 10%.
  • FME25+ closed around 100 U.S. clinics in 2026, risking patient leakage to DaVita.
  • AB 290 litigation and premium-assistance rules threaten U.S. reimbursement economics and legal spend.

What makes Fresenius Medical Care unique

  • Fresenius Medical Care controls dialysis care, equipment, labs, and specialty pharmacy end-to-end.
  • Its 5008X CAREsystem reached around 100 clinics and 100,000 treatments by May 2026.
  • kinexus and TherapyWise deepen its software moat across home dialysis and kidney therapy.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-3%

2 year growth

-3%
Business Wire
Mar 28th, 2024
Compsych Corporation Announces 2023 Health At Work Award Winners

CHICAGO--(BUSINESS WIRE)--ComPsych® Corporation, the world’s largest provider of mental health services and GuidanceResources® for life, today announced the honorees of the 2023 Health at Work Awards. Now in its 19th year, the ComPsych Health at Work Awards recognize organizations across a variety of sizes, industries and locations who have prioritized the health and well-being of their employees by providing innovative, multi-platform programs. “We’re thrilled to honor these stellar organizations for the investment they’ve made in building cultures that value employee mental health and wellness,” said Dr. Richard A. Chaifetz, Founder, Chairman and CEO of ComPsych. “In recent years we’ve seen a rise in anxiety as well as people needing to take leaves of absence due to mental health challenges across the workforce

U.S. Securities and Exchange Commission
Feb 12th, 2024
SEC FORM D

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.

U.S. Securities and Exchange Commission
Feb 12th, 2024
SEC FORM D

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.

U.S. Securities and Exchange Commission
Dec 6th, 2023
SEC FORM D

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.

Home Health Provider
Feb 17th, 2023
Improving Access & Timely Care For Vulnerable Patients Referred To Home Health Via Telehealth Physician Support

Royal Philips (NYSE: PHG AEX: PHIA), a global leader in health technology, today announced the debut of its eCareManager 4.1 enterprise telehealth software at the American Telemedicine...